Table 1 Clinical characteristics of responders and non-responders.

From: NKp30+ NK cells are associated with HBV control during pegylated-interferon-alpha-2b therapy of chronic hepatitis B

 

Responders (n = 17)

Non-responders (n = 75)

Gender (M/F)

10/7

58/17

Age, years

27 (19–42)

28 (19–45)

HBV genotype B/C

8/9

37/38

 

Baseline

End of follow-up

Baseline

End of follow-up

HBV-DNA, Log10IU/mL

8.1 ± 7.7

2.5 ± 2

8.5 ± 8.3

7.9 ± 7.2

HBsAg, IU/mL

14,091 ± 3,595

2,142 ± 823

22,175 ± 3,278

12,540 ± 1,705

Anti-HBsAg positive

0/17 (0%)

0/17 (0%)

0/75 (0%)

0/75 (0%)

HBeAg, COI

429.2 ± 113.8

0.24 ± 0.059*

6,162 ± 1,371

404.8 ± 60.6

Anti-HBeAg positive

0/17 (0%)

17/17 (100%)

0/75 (0%)

27/75 (36%)

Anti-HBcAg positive

17/17 (100%)

17/17 (100%)

75/75 (100%)

75/75 (100%)

ALT, U/L

217 (80–580)

21 (10–33)

218 (75–530)

124 (19–1107)

AST, U/L

108 (50–244)

30 (19–49)

117 (24–346)

39 (17–141)

  1. *HBeAg negative was defined as HBeAg <1 COI. Unless otherwise indicated, values are median (range). Values for HBV-DNA, HBsAg, and HBeAg are median ± SEM. ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B envelope antigen; COI, cutoff index.
Back to article page